Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629280 | 0.83 | POLB (0.35) | GBA1ALDH1A1POLBHCAR3CYP2D6 | |
| SCHEMBL9924584 | 0.80 | GBA1 (0.48) | AOC3GBA1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL2629283 | 0.79 | HRH3 (0.44) | POLBHCAR3CYP2D6HRH1CYP2C19 | |
| SCHEMBL9925938 | 0.78 | AOC3 (0.35) | AOC3GBA1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7993678 | 0.78 | POLB (0.37) | POLBHCAR3CYP2D6HRH1 | |
| SCHEMBL12186836 | 0.77 | AOC3 (0.34) | AOC3GBA1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21769321 | 0.77 | PIK3CD (0.39) | AOC3GBA1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL46324 | 0.77 | MEN1 (0.37) | ALDH1A1HSD17B10CYP1A2CLK4CYP3A4 | |
| SCHEMBL179514 | 0.74 | AOC3 (0.33) | AOC3GBA1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL9924593 | 0.74 | TRPV1 (0.36) | AOC3GBA1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| EP-2240452-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES AS PI3 KINASE MODULATORS, THEIR COMPOSITIONS AND USES | INTELLIKINE LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| WO-2009088986-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009088990-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009046448-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | AOC3 2839/4885GBA1 1016/4885PIK3CD 4/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | AOC3 2154/4885GBA1 856/4885PIK3CD 7/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | AOC3 2839/4885GBA1 1016/4885PIK3CD 4/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | AOC3 4190/4885GBA1 702/4885PIK3CD 8/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | AOC3 2522/4885GBA1 635/4885PIK3CD 6/4885 |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | ORC3, OXSR1, OSTC | AOC3 291/4885GBA1 1338/4885PIK3CD 1067/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | AOC3 4168/4885GBA1 2661/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.